Holtec Nuclear launches IPO roadshow at up to $18 per share
Holtec Nuclear Corporation has launched the roadshow for its initial public offering (IPO) on the Nasdaq Global Select Market, offering 50 million Class A common shares at an indicative price of between $15 and $18 each. At the top of that range the offering would raise approximately $900 million before underwriter fees, with a further 7.5 million shares available via a 30-day greenshoe option that could lift gross proceeds to just under $1.035 billion. The company intends to trade under the ticker symbol HNUC.
J.P. Morgan, Goldman Sachs, Guggenheim Securities, Citigroup and BofA Securities are acting as joint book-running managers, alongside Morgan Stanley, Cantor, BMO Capital Markets and Oppenheimer. The breadth of the syndicate signals an intention to reach both institutional and retail investors across the US market. A registration statement has been filed with the Securities and Exchange Commission but had not yet become effective at the time of announcement.
The company
Holtec is a New Jersey-headquartered multinational with operations on five continents, holding more than 200 granted patents and supplying products and services to more than 150 nuclear reactors worldwide. Its core business spans reactor design, engineering, manufacturing, licensing and decommissioning services.
The company's most closely watched asset is its SMR-300, a small modular reactor (SMR) built around passive safety systems that eliminate the need for active cooling interventions in an emergency. Holtec expects the first two SMR-300 units to be deployed at its own Palisades site in Michigan. The same site is also the subject of a separate and historically significant project: the recommissioning of the Palisades nuclear power plant, which would become the first commercial reactor in the United States to be restarted after a permanent shutdown. Holtec holds Nuclear Regulatory Commission authorisation as operator of the Palisades plant. Beyond nuclear, the company said it is expanding into solar generation and long-duration energy storage (LDES), technologies it positions as complementary to the SMR-300 product line.
Market context
Nuclear power has re-entered mainstream energy-transition investment conversations after years on the margins, driven by three converging forces: tightening grid reliability requirements as wind and solar capacity grows, surging power demand from data centres and AI workloads, and a reassessment of carbon-free baseload options. SMRs are at the centre of that revival. Multiple developers, including NuScale, X-energy and TerraPower, are competing for the first commercial deployments in the US, while UK and Canadian regulators are running parallel licensing processes.
Holtec's offering arrives at a relatively receptive moment for nuclear capital markets. The US Inflation Reduction Act's production tax credit for existing nuclear generation has improved the economics of operating plants, and the Department of Energy has made loan guarantees available for advanced reactor projects. The Palisades recommissioning was supported by a conditional $1.52 billion loan guarantee from the DOE, a figure disclosed in prior public reporting rather than in this release. Investors will want to read the full prospectus to understand how IPO proceeds will be allocated across the SMR programme, the recommissioning project and the LDES expansion.
What to watch
The pricing and sizing of the offering will be the immediate market signal. If Holtec prices at the top of the range and the greenshoe is exercised in full, the raise would be among the larger cleantech IPOs of 2026. The more substantive question for investors is the timeline to revenue from the SMR-300: advanced reactors typically face multi-year licensing and construction schedules before commercial operation. Progress on NRC licensing milestones for the SMR-300 and the restart date for Palisades will be the key operational indicators to track post-listing.